Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Wave Life Sciences Ltd., a biotechnology company focused on RNA medicines, announced it will host a live webcast and conference call on May 8, 2025, at 8:30 a.m. ET to discuss its first quarter 2025 ...

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, today announced it will release its financial results for the second quarter of fiscal year ...

NEW YORK--(BUSINESS WIRE)--Check, the leading payroll infrastructure company that pioneered the ability for platforms to embed payroll into their products, today announced its partnership with Wave, ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, ...